FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a selected structure to AMC, which specifically binds to a complex containing alpha-fetoprotein (AFP) peptide and a protein of a main histocompatibility complex (MHC) of the I class with Kd approximately from 0.1 pM to approximately 500 pM, to a composition containing it, as well as to a nucleic acid encoding it, and to a cell expressing it. A selected antibody to AMC or its antigen-binding fragment, which specifically binds to a complex containing alpha-fetoprotein (AFP) peptide and a protein of a main histocompatibility complex (MHC) of the I class, a composition containing it, as well as a nucleic acid encoding it, and a cell expressing it are also disclosed. The invention also relates to a method for detecting a cell presenting a complex containing AFP peptide and MHC protein of I class on its surface, as well as to a method for determining, whether an individual suffers from AFP-positive disease, using the above-mentioned structure.
EFFECT: invention allows for effective treatment of an individual suffering from AFP-positive disease.
31 cl, 26 dwg, 10 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS | 2017 |
|
RU2755503C2 |
HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
Authors
Dates
2021-08-25—Published
2016-04-01—Filed